EP Patent

EP3133070B1 — Eliglustat (genz 112638) as inhibitor of glucosylceramide synthase for use in a method of treating fabry's or gaucher's disease, the method comprising adjusting the individual therapeutical dose to the p-450 metabolism of the patient

Assigned to Genzyme Corp · Expires 2019-08-14 · 7y expired

What this patent protects

Patent listed against eliglustat-tartrate.

Drugs covered by this patent

Patent Metadata

Patent number
EP3133070B1
Jurisdiction
EP
Classification
—
Expires
2019-08-14
Drug substance claim
No
Drug product claim
No
Assignee
Genzyme Corp
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.